Intellia Q4 net loss $128.9M; cuts workforce 27%, ends NTLA-3001

Intellia Therapeutics, Inc.

2024-FY EPS reported -$5.25 revenue$57,877,000

Q4 2024 net loss $128.9M vs $132.2M prior year; revenue $12.9M.
Ended 2024 with $861.7M cash; funding into first half of 2027.
Workforce reduction of ~27% in 2025; expects $8M severance charges.
Phase 3 HAELO (NTLA-2002) dosed first patient; BLA submission planned H2 2026.
Enrollment in MAGNITUDE (nex-z for ATTR-CM) ahead of projections, >550 patients by year end.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.